Hema Now: Episode 26: Highlights from the 2025 IMS Meeting - European Medical Journal

This site is intended for healthcare professionals

Hema Now: Episode 26: Highlights from the 2025 IMS Meeting

Hematology

Hema Now | Episode 26

This episode provides timely coverage of the 2025 Meeting of the International Myeloma Society (IMS). Claudio Cerchione highlights the most important developments from the Annual Meeting, offers his reflections on the evolving treatment landscape, and discusses the role of research and collaboration in moving closer to a cure for myeloma.

Claudio Cerchione

 

Claudio Cerchione

Claudio Cerchione is a haematologist and researcher at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

He specialises in multiple myeloma, amyloidosis, and other plasma cell disorders, and has contributed to numerous national and international clinical trials. His work focuses on advancing personalised treatment strategies and improving outcomes through innovative, patient-tailored care.

 

Timestamps 

00:00 – Introduction 

02:08 – Reflections on his own career 

04:20 – Claudio’s initial interest in the field 

06:46 – Key takeaways from IMS 2025 Meeting 

10:09 – Any potential gaps in coverage? 

11:50 – How different patient groups are identified 

13:30 – Minimal residual disease 

16:15 – Impact of medical societies 

20:24 – Translating new findings into clinical practice 

23:44 – Improving the accessibility of treatments 

26:45 – Claudio’s key takeaways from IMS 2025 Meeting 

Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ. 

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.